Combination Therapy for Fibrosis Using Peptide and Small Molecule Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) are limited, with no cure available and existing medications like pirfenidone showing limited efficacy and adverse effects, necessitating the development of novel anti-fibrosis therapies.
Innovation Solution
A combination of antifibrotic agents, including peptides with specific amino acid sequences and pharmacologically acceptable salts, is administered to patients to treat fibrosis, targeting pathways such as TGF-β and PDGF, with peptides like MRVIRMCLGVGLLGDLAG and its modifications being used in conjunction with established antifibrotic agents like nintedanib and pirfenidone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifibrotic agents like pirfenidone are used, then treatment of fibrosis is provided, but adverse effects in digestive organs and photo toxicity occur
Solution Approach 1:
The patent segments the treatment approach by using multiple antifibrotic agents with different mechanisms of action simultaneously. Instead of relying on a single agent like pirfenidone that causes adverse effects, the invention divides the therapeutic strategy into multiple components (different antifibrotic agents) that work together to achieve better efficacy while potentially reducing the harmful effects associated with each individual agent
Solution Approach 2:
The patent applies the composite materials principle by combining multiple antifibrotic agents into a composite therapy regimen. This composite approach integrates agents with different mechanisms (e.g., TGF-β pathway inhibitors, PDGF pathway inhibitors, and other antifibrotic compounds) to create a synergistic treatment that addresses the limitations of single-agent therapy while mitigating adverse effects
2Reliability
If existing antifibrotic therapies are used, then fibrosis treatment is provided, but efficacy is limited
Solution Approach 1:
The patent merges multiple antifibrotic agents into a single combination therapy regimen. By combining agents that target different fibrotic pathways (such as TGF-β inhibitors, PDGF inhibitors, and other antifibrotic compounds), the invention creates a synergistic effect that overcomes the limited efficacy of individual agents and addresses the multifaceted nature of fibrotic disease
Solution Approach 2:
The patent creates a universal treatment approach that can address multiple fibrotic pathways simultaneously. The combination therapy regimen is designed to be multi-functional, targeting various mechanisms of fibrosis (TGF-β signaling, PDGF signaling, oxidative stress, inflammation) with a single therapeutic strategy that can be applied across different fibrotic conditions
Data Source
AI summary
The disclosures herein relate to materials and methods and combinations effective for the treatment of fibrosis.